This article is
- freely available
Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient
Grupo de Micobacterias, Unidade de Microbacteriologia, Centro de Malaria e outras Doenças Tropicais (CMDT), Institute of Hygiene and Tropical Medicine, Universidade Nova de Lisboa, Rua Junqueira 100, 1349-008 Lisbon, Portugal
Department of Medical Microbiology and Immunobiology, University of Szeged, Dóm tér 10, 6720 Szeged, Hungary
* Author to whom correspondence should be addressed.
Received: 13 August 2012; in revised form: 10 September 2012 / Accepted: 11 September 2012 / Published: 17 September 2012
Abstract: This mini-review provides the entire experimental history of the development of the old neuroleptic thioridazine (TZ) for therapy of antibiotic resistant pulmonary tuberculosis infections. TZ is effective when used in combination with antibiotics to which the initial Mycobacterium tuberculosis was resistant. Under proper cardiac evaluation procedures, the use of TZ is safe and does not produce known cardiopathy such as prolongation of QT interval. Because TZ is cheap, it should be considered for therapy of XDR and TDR-Mtb patients in economically disadvantaged countries.
Keywords: pulmonary tuberculosis; thioridazine; in vitro activity; ex vivo activity; cures the mouse of MDR-Mtb infections; XDR-TB; TDR-TB; cures the human of an XDR-TB infection; mechanisms of action; inhibitor of efflux pumps; enhances killing of intracellular Mtb
Article StatisticsClick here to load and display the download statistics.
Notes: Multiple requests from the same IP address are counted as one view.
Cite This Article
MDPI and ACS Style
Amaral, L.; Molnar, J. Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals 2012, 5, 1021-1031.
Amaral L, Molnar J. Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient. Pharmaceuticals. 2012; 5(9):1021-1031.
Amaral, Leonard; Molnar, Joseph. 2012. "Why and How the Old Neuroleptic Thioridazine Cures the XDR-TB Patient." Pharmaceuticals 5, no. 9: 1021-1031.